



## **Chembio Diagnostics to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020**

March 3, 2020

MEDFORD, March 03, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the fourth quarter and full year 2019 after the close of trading on Thursday, March 12, 2020.

The company's management team will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing 877-407-0778 from the US or 201-689-8565 from outside the US or by accessing [www.chembio.com/investors/calendar-of-events/](http://www.chembio.com/investors/calendar-of-events/). A replay of the call will be available by dialing 877-481-4010 from the US or 919-882-2331 from outside the US (using passcode 33460) or by accessing [www.chembio.com/investors/calendar-of-events/](http://www.chembio.com/investors/calendar-of-events/).

### **About Chembio Diagnostics**

Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases. The company's patented DPP technology platform, which uses a small drop of blood from the fingertip, provides high-quality, cost-effective results in approximately 15 minutes. Coupled with Chembio's extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease, a number of which applications are under active development with collaboration partners. Chembio's products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. Learn more at [www.chembio.com](http://www.chembio.com).

*DPP is Chembio's registered trademark. For convenience, this trademark appears in this release without ® symbols, but that practice does not mean that Chembio will not assert, to the fullest extent under applicable law, its rights to its trademark.*

### **Investor contact:**

Philip Taylor  
Gilmartin Group  
(415) 937-5406  
[investor@chembio.com](mailto:investor@chembio.com)



Source: Chembio Diagnostics, Inc.